Study finds bebtelovimab therapy lacks efficacy in patients infected with SARS-CoV-2 Omicron subvariants medrxivpreprint uarizona VCU SARSCoV2 Omicron coronavirus covid COVID19 antibody
By Bhavana KunkalikarDec 13 2022Reviewed by Danielle Ellis, B.Sc. In a recent study posted to the medRxiv* preprint server, researchers assessed the impact of bebtelovimab monoclonal antibody in the treatment of high-risk severe acute respiratory syndrome coronavirus 2 Omicron variant-infected patients.
This retrospective cohort research of COVID-19-positive individuals was undertaken from 5 April 2022 and 1 August 2022. BEB MAb-treated patients, as well as untreated individuals from Banner Health Care System's electronic health records . The alternative BEB MAb treatment was approved for mild-to-moderately severe COVID-19 among adults at high risk of illness progression and in children over 12 years who weighed 40 kg or more.
Results In the post-propensity-matched group, the median age of the subjects from the BEB MAb therapy group was 64 years, including 43% men and 78.7% White individuals, of which 68.6% were completely immunized against COVID-19.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
SARS-CoV-1 and SARS-CoV-2 spike proteins utilize different mechanisms to bind to ACE2SARS-CoV-1 and SARS-CoV-2 spike proteins utilize different mechanisms to bind to ACE2 ACE2 Angiotensin Coronavirus COVID MERSCoV SARSCoV2 FrontMicrobiol UTEP HowardU
Weiterlesen »
Bioengineered soluble ACE2 for brain protection against SARS-CoV-2 infectionBioengineered soluble ACE2 for brain protection against SARS-CoV-2 infection biorxivpreprint NorthwesternU ChariteBerlin UChicago brain SARSCoV2 ACE2 COVID19 coronavirus covid
Weiterlesen »
Detection of unreported infections based on SARS-CoV-2 antibody seroprevalenceDetection of unreported infections based on SARS-CoV-2 antibody seroprevalence Antibody Coronavirus COVID SARSCoV2 LancetRH_Americ CDCgov QuestDX Labcorp
Weiterlesen »
Study shows emerging Omicron sublineages efficiently evade neutralization independent of immunization historyStudy shows emerging Omicron sublineages efficiently evade neutralization independent of immunization history TheLancetInfDis DPZ_eu uniGoettingen Omicron COVID19 coronavirus covid immunization
Weiterlesen »
Study suggests persistent inflammatory response triggered by SARS-CoV-2 may be responsible for observed sequelae in PASC patientsStudy suggests persistent inflammatory response triggered by SARS-CoV-2 may be responsible for observed sequelae in PASC patients biorxivpreprint unidue ChariteBerlin SARSCoV2 inflammation inflammatory covid coronavirus COVID19
Weiterlesen »
Clinical efficacy and safety of two injections of a bivalent vaccine as a primary series during a period of Omicron circulationClinical efficacy and safety of two injections of a bivalent vaccine as a primary series during a period of Omicron circulation medrxivpreprint EmoryUniversity harvardmed fredhutch HopkinsMedicine vaccine vaccination COVID19 coronavirus covid
Weiterlesen »